WORKSHOP
VACCINES IN THE MANAGEMENT OF CANCER:
Where we are heading
Saturday November 15 and Sunday November, 16, 2008
Molecular Biotechnology Center, Aula Galileo, Via Nizza 52, 10126, Torino

SATURDAY, NOVEMBER 15
9,00 am-1,00 pm

Guido Forni, Torino, Italy, An introduction

Jay Berzofsky, Bethesda, USA, The role of NKT cell subsets in the regulation of tumor immunity

Kees Melief, Leiden, Netherlands, Conditions for success of therapeutic vaccination against the oncongenic proteins of high risk Human Papilloma Virus

Soldano Ferrone, Pittsburgh, USA, High molecular weight melanoma-associtaed antigen as target for immunotherapy

Pedro Romero, Lausanne, Switzerland, Peptide based vaccines in melanoma. Lessons and perspectives

1,00-2,00 LUNCH

2,00- 6,30 pm

Gustav Gaudernack, Oslo, Norway, Cancer vaccines targeting key molecules in carcinogenesis: What have we learned during 15 years of clinical trials?

Mac Cheever, Seattle, USA, Prioritization of cancer antigens and immunotherapy agents for vaccine trials

Larry Kwak, MD Anderson, Houston, Texas, Translational development of vaccines for hematologic cancers

Giorgio Inghirami, Torino, Italy, Concluding remamrks and issues for tomorrow
HOW TO DESIGN A RATIONALE CLINICAL TRIAL FOR TESTING A NEW VACCINE: between the idea and money

Chairmen:

Michael Papamicail, Athens, Greece
Giuseppe Masucci, Stockholm, Sweden
Federica Pericle, El Paso, Texas
Licia Rivoltini, Milan, Italy

Critical issues in clinical vaccine design
• Adjuvants
• Regulatory cells
• Suppressor activities
• Combination therapies

How to design a clinical trial:
• Number of patients,
• Time frame
• Clinical and surrogate end-points
• Should we get rid of Treg and myeloid suppressor cells?
• Combination therapies: are these possible in Phase I trials?

Who will sponsor a vaccine and a vaccine based trial?
• Costs
• Patents
• Sponsors